Search results for Coultreon Biopharma

Immunology-Focused Coultreon Adds $125M for Pills That Pack the Punch of Injectable Biologics

Coultreon Biopharma’s lead drug candidate, acquired from Galapagos, is a small molecule designed to selectively inhibit a novel immunology target called SIK3. The Series A financin...

Coultreon banks $125M to support testing of former Galapagos immune drug

Backed by Novo Holdings, Regeneron’s venture arm and several others, the biotech believes an oral drug licensed from Galapagos might hold potential treating many immunological dise...

Rebranded Belgian biotech lands $125M for rescued Galapagos drug candidates

After launching in 2025 as a refuge for shipwrecked assets from Galapagos, Onco3R Therapeutics is rebranding as Coultreon Biopharma and filling its treasure chest with a $125 milli...

LOTTE Biologics Expands Antibody Manufacturing Agreement with Ottimo Pharma

SEOUL, South Korea, May 17, 2026 /PRNewswire/ -- LOTTE Biologics (Co-CEOs James Park and Yooyeol Shin) announce an expansion of its collaboration with Ottimo Pharma, an innovative...

Legend Biotech

Legend Biotech Anonymous (not verified) Fri, 05/29/2026 - 14:41 field_thread_url https://cafepharma.com/boards/threads/legend-biotech.701129/...

Legend Biotech

Legend Biotech Anonymous (not verified) Wed, 05/27/2026 - 11:39 field_thread_url https://cafepharma.com/boards/threads/legend-biotech.701129/...

<![CDATA[Regeneron Enters $2.3 Billion Collaboration with Parabilis Medicines to Discover & Develop Multiple Ther...

<![CDATA[Regeneron Enters $2.1 Billion Radiopharma Collaboration with Telix Pharmaceuticals ]]>

CPC Biotech Launched to Offer a Fluid Management Component Portfolio

CPC Biotech’s solutions support a range of applications in bioprocessing operations, spanning the upstream and downstream biologic drug manufacturing process, as well as cell and g...

<![CDATA[UCB Enters $2.2 Billion Agreement to Acquire Candid Therapeutics ]]>

Cellares and ProTgen Automate Manufacturing of Progenitor T-Cell Therapy for Blood Cancer

The partnership will automate manufacturing and quality control of ProT-096, ProTgen’s personalized progenitor T-cell therapy for refractory leukemia and other hematologic malignan...

<![CDATA[Roche and C4 Therapeutics Expands Partnership with $1 Billion Collaboration Agreement ]]>

Lilly makes preclinical ADC specialist CrossBridge its latest acquisition in vague $300M deal

Eli Lilly has turned its attention down south with a $300 million biobuck acquisition of Houston-based CrossBridge Bio, aiming to advance its dual-payload antibody-drug conjugate (...

Beeline, a Bain-backed biotech, debuts with immune drugs from Bristol Myers

Equipped with $300 million, Beeline has an oral medicine for the treatment of lupus as well as other experimental drugs targeting autoimmune diseases.

<![CDATA[Gilead Enters $5 Billion Agreement to Acquire Tubulis ]]>

Beigene

Beigene Anonymous (not verified) Mon, 05/25/2026 - 11:38 field_thread_url https://cafepharma.com/boards/threads/beigene.637588/ board na...

<![CDATA[Obsidian Therapeutics and Galera Therapeutics Enter $350 Million Merger Agreement]]>

Avalo shares spike on skin drug data; BioNTech to cut staff

Avalo reported study success in what’s proven to be a tough-to-treat skin disease. Elsewhere, BioNTech announced plans to close multiple plants and Madrigal picked up an RNA-based...

NJ Bio Inc., Ajinomoto Bio‑Pharma Services agree to collaborate to bolster support for antibody-drug conjugate developme...

NJ Bio Inc., a provider of integrated drug discovery and development services and Ajinomoto Bio‑Pharma Services, a biopharmaceutical manufacturing services and platform technologie...

Beigene

Beigene Anonymous (not verified) Thu, 04/30/2026 - 14:18 field_thread_url https://cafepharma.com/boards/threads/beigene.637588/ board na...

UCB to acquire Candid in $2.2B bet on bispecifics for autoimmune diseases

The buyout involves a portfolio of antibody drugs Candid licensed from China-based biotechs and that UCB sees as part of the “next wave” of care for immunological conditions.

<![CDATA[Biogen Enters $5.6 Billion Agreement to Acquire Apellis Pharmaceuticals ]]>

This Startup Aims to Upend Biologic Drug Production With Implantable ‘Cell Factories’

Duracyte’s implants employ cells engineered to produce therapeutic protein, bypassing the complexities of traditional biologics manufacturing. The startup’s marriage of biotechnolo...

Citius Oncology, Inc. Secures Up to $36.5 Million in Debt and Equity Capital to Accelerate LYMPHIR® Commercialization

Avenue Capital Group to provide up to $25 Million via Senior Credit Facility with an initial $10 million tranche funded at closing; additional tranches subject to certain condition...